According to another investigation, Spear and colleagues developed T cells engineered to express NKG2D-based CAR constructs (referred to as chNKG2D-CAR-Ts) and demonstrated how adoptive transfer of these cells resulted in sufficient antitumor effects against NKG2DL-positive and NKG2DL-negative ovarian cancer tumors and how chNKG2D-CAR-T treatment conferred antitumor immunity against NKG2DL-deficient ovarian cancer cells (126). The gene discussed is KLRK1; the disease is ovarian carcinoma.